2020 Apr 01

New citation required but conclusions have not changed

A new co‐author (CS) has joined the review and the previous co‐author (CO) has stepped down.

Despite the addition of one new study to this review, our conclusions remain the same.

2020 Apr 01

New search has been performed

A search of the Cochrane Cystic Fibrosis and Genetic Disorders Cystic Fibrosis Trials Register identified five new references which were potentially eligible for inclusion in the review.

One reference was the full paper to an abstract previously listed awaiting classification and included at this update (Hanssens 2016).

Two were references to a single new study that was excluded (O'Connor 2016). Two were single references to two further new studies that were also excluded (Pastor 2019; Vericel 2019).

A study previously listed as awaiting assessment has been excluded (O'Sullivan 2011).

A summary of findings table has been added to the review.

2020 Feb 27

Amended

Clarification statement added from Alan Smyth, Co‐ordinating Editor on 27 February 2020: This review was found by the Cochrane Funding Arbiters, post‐publication, to be noncompliant with the Cochrane conflict of interest policy, which includes the relevant parts of the Cochrane Commercial Sponsorship Policy. The review will be updated by August 2020; both authors of the future update will be free of conflicts.

Current version (post‐publication): Colleen Oliver: no conflicts of interest. Helen Watson received funding for travel from Abbott Nutrition (manufacturer of ENSURE® ORIGINAL THERAPEUTIC NUTRITION with omega‐3 fatty acid ALA) (June 2013).

2013 Nov 26

New citation required but conclusions have not changed

Nikki Jahnke has stepped down as co‐author and Helen Watson is the new co‐author on this review.

No new studies were included in this update of the review, therefore our conclusions remain the same.

2013 Nov 26

New search has been performed

A search of the Cystic Fibrosis & Genetic Disorders Group's Cystic Fibrosis Trials Register identified four new references. Three of these related to a study previously listed as ongoing, including the full paper (Alicandro 2013); and the fourth was a reference to an abstract of a new study. We have excluded the Alicandro study and the new abstract by O'Sullivan is listed as awaiting classification until we can obtain further information to allow us to include or exclude the study (O'Sullivan 2011).

2011 Mar 10

New citation required but conclusions have not changed

The title of the review has been amended removing 'from fish oils' and hence expanding the different potential sources of omega‐3 fatty acids to be considered for this review.

One of the authors, Dr Mark Everard, has stepped down from the review team. A new author, Nikki Jahnke, joined the team for this update. Another author, Tracy N'Diaye, has not been actively involved in this update of the review and is currently not listed on the citation.

2011 Mar 10

New search has been performed

A search of the Cystic Fibrosis Trials Register identified eleven new references to six trials which were potentially eligible for inclusion in the review. Three of these studies were excluded (Christophe 1992; Lloyd‐Still 2006; van Biervliet 2008). One study was listed as awaiting assessment (Starling 1988). One study was listed as ongoing (Colombo 2008). One study was included in the review (Keen 2010).

2010 Sep 08

Amended

Contact details updated.

2009 Nov 11

Amended

Contact details updated.

2009 Aug 12

Amended

Contact details updated.

2008 Jun 13

New search has been performed

A search of the Group's Cystic Fibrosis Trials Register did not identify any studies potentially eligible for inclusion in the review.

2008 Jun 02

Amended

Converted to new review format.

2017 May 10

Amended

Converted to new review format.